Jennifer Uhrlaub

Title: Jennifer Uhrlaub: Innovator in Viral Detection and Treatment

Introduction

Jennifer Uhrlaub is a prominent inventor based in Tucson, AZ (US). She has made significant contributions to the field of viral detection and treatment, holding 2 patents that showcase her innovative work. Her research focuses on developing methods and systems to combat viral infections, particularly those caused by SARS-CoV-2 and alphaviruses.

Latest Patents

One of her latest patents is titled "Serological assays for SARS-CoV-2." This invention provides a test system that includes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor binding domain (RBD) antigen, SARS-CoV-2 S2 antigen, and binding moieties that specifically bind to human IgG, human IgA, and human IgM. The patent also outlines methods for detecting SARS-CoV-2 antibodies in a sample using this test system.

Another significant patent is "Methods and compositions for treating an alphavirus infection." This invention details methods and pharmaceutical compositions aimed at preventing, treating, or suppressing symptoms associated with alphavirus infections. Specifically, it focuses on inhibiting the activity and/or expression of Transforming Growth Factor Beta (TGF-β) in subjects suffering from or at risk of alphavirus infections.

Career Highlights

Jennifer Uhrlaub is affiliated with The University of Arizona, where she continues her research and development efforts. Her work has garnered attention for its potential impact on public health, especially in the context of emerging viral threats.

Collaborations

Jennifer collaborates with esteemed colleagues, including Janko Nikolich-Zugich and Ryan Sprissler, who contribute to her research initiatives and enhance the scope of her inventions.

Conclusion

Jennifer Uhrlaub is a dedicated inventor whose work in viral detection and treatment is paving the way for advancements in public health. Her innovative patents reflect her commitment to addressing critical health challenges.